BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20096776)

  • 1. Reversibility of the effects of the chemotherapeutic regimen for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone, on the male rat reproductive system and progeny outcome.
    Delbès G; Vaisheva F; Luu T; Marcon L; Hales BF; Robaire B
    Reprod Toxicol; 2010 Jun; 29(3):332-8. PubMed ID: 20096776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the chemotherapeutic agents for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome.
    Vaisheva F; Delbes G; Hales BF; Robaire B
    J Androl; 2007; 28(4):578-87. PubMed ID: 17409468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility.
    Bieber AM; Marcon L; Hales BF; Robaire B
    J Androl; 2006; 27(2):189-200. PubMed ID: 16278370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat.
    Marcon L; Hales BF; Robaire B
    J Androl; 2008; 29(4):408-17. PubMed ID: 18296477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison between CHOP-PVP and CHOP protocols for non-Hodgkin's lymphoma.
    Gan H; Zhang F; Lin Y
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):397-9. PubMed ID: 12408775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
    J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
    Alliot C
    J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].
    Li YH; Jiang WQ; Huang HQ; Xu RH; Lin TY; Xia ZJ; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):401-3. PubMed ID: 12703998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necrotizing leukoencephalopathy following CHOP chemotherapy.
    Blaes AH; Santa-Cruz KS; Lee CK; Hui SK; Peterson BA
    Leuk Res; 2008 Oct; 32(10):1611-4. PubMed ID: 18378307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
    Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
    Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study.
    Cocconi G; Franciosi V; Dodero A; Bologna A; Vasini G; De Lisi V; Di Blasio B; Ceci G; Camisa R; Cascinu S
    Am J Clin Oncol; 2003 Dec; 26(6):535-42. PubMed ID: 14663368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
    Spina M; Simonelli C; Tirelli U
    J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.